European regulators recommend a novel checkpoint inhibitor and antibody-drug conjugate combination for young patients with refractory Hodgkin lymphoma offering durable clinical benefits.
Medscape News Europe
Source link : https://www.medscape.com/viewarticle/ema-backs-dual-therapy-young-hodgkin-lymphoma-patients-2026a10003ch?src=rss
Author :
Publish date : 2026-02-03 13:45:00
Copyright for syndicated content belongs to the linked Source.